Quarterly ResultAug 6, 2026, 06:13 AM
Haemonetics Q1 Revenue $339.4M, EPS $0.72; Raises FY27 Guidance
AI Summary
Haemonetics Corporation reported strong financial results for the first quarter of fiscal 2027, with revenue increasing 5.6% to $339.4 million and organic revenue growing 5.9%. Diluted earnings per share were $0.72, while adjusted diluted earnings per share reached $1.14. Following this performance, the company raised its full-year fiscal 2027 guidance for both reported and organic revenue, citing a strong start with gains in Plasma share, sustained momentum in Blood Management Technologies, and growth in Interventional Technologies.
Key Highlights
- Q1 FY27 Revenue: $339.4 million, up 5.6% year-over-year.
- Q1 FY27 Organic Revenue Growth: 5.9%.
- Q1 FY27 Diluted EPS: $0.72.
- Q1 FY27 Adjusted Diluted EPS: $1.14.
- Q1 FY27 Cash flow from operating activities: $52 million.
- Q1 FY27 Free cash flow: $39 million.
- Raised FY27 Reported Revenue Guidance to 5-8% (from 4-7%).
- Raised FY27 Organic Revenue Guidance to 4-7% (from 3-6%).
Price Impact
More from HAE